1
|
Varghese J, Schmale I, Mickelsen D, Hansen M, Newlands S, Benoit D, Korshunov V, Ovitt C. Localized Delivery of Amifostine Enhances Salivary Gland Radioprotection. J Dent Res 2018; 97:1252-1259. [PMID: 29634396 PMCID: PMC6151913 DOI: 10.1177/0022034518767408] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Radiotherapy for head and neck cancers commonly causes damage to salivary gland tissue, resulting in xerostomia (dry mouth) and numerous adverse medical and quality-of-life issues. Amifostine is the only Food and Drug Administration-approved radioprotective drug used clinically to prevent xerostomia. However, systemic administration of amifostine is limited by severe side effects, including rapid decrease in blood pressure (hypotension), nausea, and a narrow therapeutic window. In this study, we demonstrate that retroductal delivery of amifostine and its active metabolite, WR-1065, to murine submandibular glands prior to a single radiation dose of 15 Gy maintained gland function and significantly increased acinar cell survival. Furthermore, in vivo stimulated saliva secretion was maintained in retrograde-treated groups at levels significantly higher than irradiated-only and systemically treated groups. In contrast to intravenous injections, retroductal delivery of WR-1065 or amifostine significantly attenuated hypotension. We conclude that localized delivery to salivary glands markedly improves radioprotection at the cellular level, as well as mitigates the adverse side effects associated with systemic administration. These results support the further development of a localized delivery system that would be compatible with the fractionated dose regimen used clinically.
Collapse
Affiliation(s)
- J.J. Varghese
- Department of Biomedical Engineering,
University of Rochester, Rochester, NY, USA
| | - I.L. Schmale
- Department of Otolaryngology, University of
Rochester, Rochester, NY, USA
| | - D. Mickelsen
- Aab Cardiovascular Research Institute,
University of Rochester, Rochester, NY, USA
| | - M.E. Hansen
- Department of Biomedical Engineering,
University of Rochester, Rochester, NY, USA
| | - S.D. Newlands
- Department of Otolaryngology, University of
Rochester, Rochester, NY, USA
- Wilmot Cancer Institute, University of
Rochester, Rochester, NY, USA
- Department of Neuroscience, University of
Rochester, Rochester, NY, USA
| | - D.S.W. Benoit
- Department of Biomedical Engineering,
University of Rochester, Rochester, NY, USA
- Center for Oral Biology, University of
Rochester, Rochester, NY, USA
- Department of Biomedical Genetics, University
of Rochester, Rochester, NY, USA
- Center for Musculoskeletal Research,
University of Rochester, Rochester, NY, USA
- Department of Orthopaedics, University of
Rochester, Rochester, NY, USA
- Department of Chemical Engineering,
University of Rochester, Rochester, NY, USA
| | - V.A. Korshunov
- Aab Cardiovascular Research Institute,
University of Rochester, Rochester, NY, USA
| | - C.E. Ovitt
- Center for Oral Biology, University of
Rochester, Rochester, NY, USA
- Department of Biomedical Genetics, University
of Rochester, Rochester, NY, USA
| |
Collapse
|
2
|
Murley JS, Kataoka Y, Baker KL, Diamond AM, Morgan WF, Grdina DJ. Manganese superoxide dismutase (SOD2)-mediated delayed radioprotection induced by the free thiol form of amifostine and tumor necrosis factor alpha. Radiat Res 2007; 167:465-74. [PMID: 17388698 DOI: 10.1667/rr0758.1] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2006] [Accepted: 11/30/2006] [Indexed: 11/03/2022]
Abstract
RKO36 cells, a subclone of RKO colorectal carcinoma cells that have been stably transfected with the pCMV-EGFP2Xho vector, were grown to confluence and then exposed to either the radioprotector WR-1065, i.e. the active thiol form of amifostine, for 30 min at doses of 40 microM and 4 mM or the cytokine tumor necrosis factor alpha (TNFalpha, TNFA) for 30 min at a concentration of 10 ng/ml and then washed. Total protein was isolated as a function of time up to 32 h after these treatments. Both doses of WR-1065 as well as the concentration of TNFalpha used were effective in elevating intracellular levels of the antioxidant protein SOD2 (also known as MnSOD) at least 15-fold over background levels as determined by Western blot analysis, while measured SOD2 activity was elevated between 5.5- and 6.9-fold. SOD2 reached a maximal level 24 h and 20 h after WR-1065 and TNFalpha treatments, respectively. The antioxidant proteins catalase and glutathione peroxidase (GPX) were also monitored over the 32-h period. In contrast to the robust changes observed in intracellular levels of SOD2 as a function of time after exposure of cells to WR-1065, catalase levels were elevated only 2.6-fold over background as determined by Western blot analysis, while GPX activity was unaffected by WR-1065 exposure. GPX protein levels were extremely low in cells, and analysis of GPX activity using a spectrophotometric method based on the consumption of reduced NADPH also revealed no measurable change as a function of WR-1065 or TNFalpha exposure. RKO36 cells either were irradiated with X rays in the presence of either 40 microM or 4 mM WR-1065 or 10 ng/ml TNFalpha or were irradiated 24 or 20 h later, respectively, when SOD2 protein levels were most elevated. The concentrations and exposure conditions used for WR-1065 and TNFalpha were not cytotoxic and had no effect on plating efficiencies or cell survival compared to untreated controls. No protection or sensitization was observed for cells irradiated in the presence of 40 microM WR-1065 or TNFalpha. Survival was elevated 1.90-fold for cells irradiated in the presence of 4 mM WR-1065. When RKO36 cells were irradiated with 2 Gy 24 h after 40 microM or 4 mM WR-1065 and 20 h after TNFalpha treatments when SOD2 levels were the most increased, survival was elevated 1.42-, 1.48- and 1.36-fold, respectively. This increased survival represents a SOD2-mediated delayed radioprotective effect. SOD2 appears to be an important antioxidant gene whose inducible expression is an important element in adaptive cellular responses in general, and the delayed radioprotective effect in particular. It can be induced by a range of agents including cytoprotective nonprotein thiols such as WR-1065 and pleiotropic cytokines such as TNFalpha.
Collapse
Affiliation(s)
- Jeffrey S Murley
- Department of Radiation and Cellular Oncology, University of Chicago, Illinois 60637, USA
| | | | | | | | | | | |
Collapse
|
3
|
Cassatt DR, Fazenbaker CA, Bachy CM, Kifle G, McCarthy MP. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Int J Radiat Oncol Biol Phys 2005; 61:901-7. [PMID: 15708273 DOI: 10.1016/j.ijrobp.2004.10.032] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2004] [Revised: 09/30/2004] [Accepted: 10/10/2004] [Indexed: 11/21/2022]
Abstract
PURPOSE The cytoprotective drug amifostine (Ethyol) protects rats from oral mucositis resulting from a single dose of gamma-irradiation. We expanded earlier studies to determine whether multiple doses of amifostine protect against fractionated or hyperfractionated radiation and whether the active metabolite of amifostine (WR-1065) accumulates in tissues upon repeated administration. METHODS AND MATERIALS Rats received amifostine daily for 5 days in conjunction with a 1-week fractionated radiation schedule and were evaluated for oral mucositis. Rats also received amifostine before the am or pm exposure or b.i.d. in conjunction with hyperfractionated radiation. To determine the pharmacokinetics of WR-1065 after repeated dosing, amifostine was given 5 days a week for 1 or 3 weeks, and rat tissue and plasma were collected at intervals during and after treatment and analyzed for WR-1065. RESULTS Amifostine protected rats from mucositis resulting from fractionated or hyperfractionated radiation. When the number of days of amifostine administration was reduced, protection was diminished. A dose of 100 mg/kg given in the morning or 2 doses at 50 mg/kg provided the best protection against hyperfractionated radiation. WR-1065 did not accumulate in tissues or tumor upon repeated administration. CONCLUSIONS Amifostine prevented radiation-induced mucositis in a rat model; protection was dose and schedule dependent.
Collapse
Affiliation(s)
- David R Cassatt
- Department of Molecular Biology/Biochemistry, MedImmune Inc. One MedImmune Way, Gaithersburg, MD 20878, USA
| | | | | | | | | |
Collapse
|
4
|
Souid AK, Fahey RC, Aktas MK, Sayin OA, Karjoo S, Newton GL, Sadowitz PD, Dubowy RL, Bernstein ML. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study. Drug Metab Dispos 2001; 29:1460-6. [PMID: 11602522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
The Pediatric Oncology Group study for metastatic Ewing's sarcoma used amifostine and mesna with the alkylating agents. To determine the fate of combined drug thiols, we measured thiol levels in plasma, red blood cells (RBC), and peripheral blood mononuclear cells (PBMC) of four patients. We also conducted analogous measurements on two patients who received mesna alone and a volunteer's blood following in vitro treatment. Thiols were labeled with monobromobimane, separated on high-pressure liquid chromatography, and detected by fluorescence. Incubation of a volunteer's blood with mesna, WR-1065, or both revealed that cellular uptake of total reducible drug was approximately 10% of plasma level for mesna but approximately 60% for WR-1065. Cellular drugs were mainly the thiol form, whereas half of the plasma drugs were disulfides. Combined incubation with both thiols did not change the extent or form of uptake. WR-1065 and mesna prevented glutathione depletion by 4-hydroperoxycyclophosphamide. Results from patients were similar. WR-1065 and mesna appeared in the cells by the end of the drug infusions, although WR-1065 uptake was more efficient than mesna. The concentration-time profiles of mesna in RBC paralleled those in plasma. Amifostine administration during mesna infusion caused transient increase in mesna levels. Both agents increased blood cysteine and decreased total reducible cysteine. Mesna alone and mesna plus amifostine prevented cellular glutathione depletion. In conclusion, mesna is imported by RBC and PBMC, but less efficiently than WR-1065. When present at equal levels, these thiols do not influence each other's uptake. Adequate dosing of either drug is necessary for protecting the cells from toxic effects of alkylating agents.
Collapse
Affiliation(s)
- A K Souid
- Department of Pediatrics, State University of New York, Upstate Medical University, Syracuse, New York, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Symon Z, Levi M, Ensminger WD, Smith DE, Lawrence TS. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. Int J Radiat Oncol Biol Phys 2001; 50:473-8. [PMID: 11380236 DOI: 10.1016/s0360-3016(01)01522-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
PURPOSE The tolerance of the liver to radiation is too low to permit an effective dose to be delivered to patients who have diffuse intrahepatic cancer. In this study we evaluated whether systemic or portal venous administration of the aminothiol compound, amifostine, could protect the normal liver from the effects of ionizing radiation without compromising tumor cell kill in a rat liver tumor model. METHODS AND MATERIALS Rats implanted with liver tumors were infused with 200 mg/kg amifostine over 15 min via the femoral or portal vein. The livers were irradiated with a single 6-Gy fraction 15-20 min after the termination of amifostine infusion. Protection of the liver was assessed by an in vitro hepatocyte micronucleus assay and tumor protection by an in vivo-in vitro clonogenic survival assay. Tissue levels of the active metabolite, free WR-1065, were determined in the tumor and in the normal liver using a specific HPLC assay with electrochemical detection. RESULTS After a 6-Gy fraction, the frequency of hepatocyte micronuclei after administration of saline, systemic amifostine, and portal venous amifostine was 18.7+/-1%, 6.8+/-1%, and 9.9+/-2%, respectively, corresponding to a radiation equivalent effect of 6 Gy +/- 0.5, 1.8 Gy +/- 0.3, and 2.5 Gy +/- 1.3, respectively. Both amifostine conditions showed considerably less radiation effect than saline-treated controls (p < 0.01); the two amifostine conditions did not differ (p = 0.3). The surviving fraction of tumor cells was not affected by amifostine treatment and was 0.03+/-0.02 and 0.05+/-0.03 for systemic and portal venous delivery and 0.06+/-0.02 for control animals (ANOVA analysis showed no significant difference of the means p = 0.34). Portal venous delivery produced significantly less WR-1065 in the tumor compared to systemic administration (54 microM +/- 36 vs. 343 microM +/- 88, respectively, p = 0.03). CONCLUSIONS Both systemic and portal venous administration of amifostine effectively protect hepatocytes from ionizing radiation without compromising tumor cell kill in a clinically relevant animal model. These findings suggest that amifostine may be a selective normal tissue radioprotectant in liver cancer and that regional/portal infusions may be preferable to systemic dosing.
Collapse
Affiliation(s)
- Z Symon
- Department of Radiation Oncology, College of Medicine-College of Pharmacy, University of Michigan, Ann Arbor 48109-0010, USA.
| | | | | | | | | |
Collapse
|
6
|
Trebenok ZA, Koshcheenko NN, Romantsev EF. [Adenosine triphosphoric acid pool in rat tissues after the administration of beta-mercaptoethylamine]. Vopr Med Khim 1980; 26:124-6. [PMID: 7368617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Pool of ATP in thymus, spleen and liver tissues of non-irradiated rats underwent distinct tissue-specific alterations just after intraperitoneal administration of hydrotartrate of beta-mercaptoethylamine (cisteamine, MEA) at e radioprotective dose 300 mg/kg. The data obtained suggest that there are marked impairments in turnover of adenylic nucleotides at the period corresponding to manifestation of the MEA radioprotective efficiency.
Collapse
|
7
|
Maisin JR, Mattelin G, Lambiet-Collier M. Chemical protection against the long-term effects of a single whole-body exposure of mice to ionizing radiation. I. Life shortening. Radiat Res 1977; 71:119-31. [PMID: 877236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
8
|
Baker DG, Leith JT. Protection of the skin of mice against irradiation with cyclotron-accelerated helium ions by 2-mercaptoethylamine. Acta Radiol Ther Phys Biol 1975; 14:561-71. [PMID: 1224998 DOI: 10.3109/02841867509132698] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Mouse skin was exposed to doses of 1 250 to 3 000 rad using a helium ion beam with modal LET of 15 keV per micron. The skin reactions were evaluated for mice treated with a topical application of 10% MEA in a cream base or a placebo 15 minutes before irradiation. A comparison of the skin reactions indicated that the MEA treatment resulted in a DMF of at least 1.2. The implication for radiation therapy was discussed.
Collapse
|
9
|
Kalaydjiev V, Konstantinova D. The effect of beta-mercaptoethylamine on the anaphylactic shock. Boll Ist Sieroter Milan 1974; 50:6-8. [PMID: 4812965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
10
|
Shiba T. [Clinical studies on the therapeutic effect of beta-mercaptoethylamine (lathyrogen) on fibrosis of the liver. II. Prevention of the development of hepatic fibrosis by use of beta-mercaptoethylamine]. Nihon Shokakibyo Gakkai Zasshi 1972; 69:265-74. [PMID: 4674099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
11
|
Hasegawa AT, Landahl HD. Dose reduction factor for radiation lethality in mice as a function of the dose of mercaptoethylamine. Radiat Res 1970; 44:738-47. [PMID: 5489168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
12
|
Filippovich IV, Koshcheenko NN, Romantzev EF. The mechanism of "biochemical shock". I. The correlation between the accumulation of some thiol radioprotectors in rat tissues and biochemical changes induced by them. Biochem Pharmacol 1970; 19:2533-40. [PMID: 5478279 DOI: 10.1016/0006-2952(70)90001-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|
13
|
Léonard A, Maisin JR, Mattelin G. Effect of a mixture of chemical protectors against X-irradiation induced testis injury in mice. Strahlentherapie 1969; 138:614-8. [PMID: 5364197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
|
14
|
Strelkov RB, Parasonchko LA. [On the central component in the mechanism of the antiradiation effect of mexamine and beta-mercaptoethylamine]. Farmakol Toksikol 1967; 30:615-6. [PMID: 5598924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
|